

EARNINGS RELEASE 3Q | 2026

November 9, 2026

Belo Horizonte, November 9, 2026

Rede Mater Dei de Saúde (“Mater Dei” or “Company”) (B3: MATD3) announces its results for the third quarter of 2026 (3Q26). Figures are presented on a consolidated basis in millions of Reais (R$), unless otherwise stated. Comparisons refer to the third quarter of 2025 (YoY) and the second quarter of 2026 (QoQ). Quarterly information complies with Brazilian and International Financial Reporting Standards (IFRS) and has been audited by independent auditors.

Consolidated Figures

Financial indicators in R$ million	3Q26	3Q25	Δ	2Q26	Δ	9M26	9M25	Δ
Operational Beds (period avg)	1,239	1,246	(0.6%)	1,225	+1.1%	1,211	1,215	(0.3%)
Patient-days (period total)	88,511	87,473	+1.2%	87,760	+0.9%	258,846	252,655	+2.5%
Occupancy Rate (period avg)	77.7%	76.3%	+1.4pp	78.7%	(1.0pp)	78.3%	76.2%	+2.1pp
Day-Hospital Occupancy Rate (avg)	83.8%	81.7%	+2.1pp	83.9%	(0.1pp)	84.0%	81.5%	+2.5pp
Average Ticket (R$ mn/Bed)	3.06	2.67	+14.6%	2.87	+6.5%	2.93	2.62	+11.9%
Net Revenue	660	568	+16.3%	614	+7.6%	1,849	1,613	+14.6%
Gross Profit	209	171	+22.2%	187	+12.0%	570	480	+18.8%
Adjusted EBITDA	148	126	+17.8%	139	+7.0%	417	338	+23.4%
EBITDA Margin	22.5%	22.2%	+0.3pp	22.6%	(0.1pp)	22.5%	20.9%	+1,6pp
Adjusted Net Income	52	27	+90.9%	45	+16.6%	134	75	+78.9%
Net Debt	731	738	-7	763	-32	731	738	-7
Net Debt/EBITDA LTM	1.4x	1.8x	(0.4x)	1.5x	(0.1x)	1.4x	1.8x	(0.4x)

Highlights




Operational and Financial

Consolidated
- ✓ Quarterly record in Net Revenue and EBITDA
- ✓ Highest quarterly average ticket in the Network, up 14.6% vs 3Q25
- ✓ Gross margin expansion of 1.6 pp vs 3Q25 and 1.3 pp vs 2Q26
- ✓ Gross Profit expansion of R$ 22 million QoQ, R$ 38 million YoY, and R$ 90 million year-to-date vs 9M25
- ✓ Net Income increase of 90.9% vs 3Q25
- ✓ R$ 32 million net debt reduction in the quarter

RMBH
- ✓ 12% Net Revenue growth vs 3Q25
- ✓ Nova Lima with 200% growth in oncology patients and 34% in surgical bookings vs 3Q25

Salvador:
- ✓ Record Net Revenue, up 19% vs 2Q26
- ✓ 425% growth in oncology patients and 13% in surgical bookings vs 3Q25

Acquired Units:
- ✓ Increase of 12% in Net Revenue vs 3T25
- ✓ 135% growth in oncology patients vs 3Q25
- ✓ HSG and EMEC achieved the highest quarterly Net Revenue in their history



Awards, Recognitions and Accreditations

- ❑ JCI Enterprise Accreditation awarded to Rede Mater Dei—the first Hospital Network in Latin America to obtain this certification—evidencing management maturity, governance strength, and standardized corporate processes aligned with clinical quality.
- ❑ Santo Agostinho Unit featured in the World's Best Specialized Hospitals 2027 ranking, positioned among the world's leading cardiology centers, reinforcing care excellence.
- ❑ Awarded the Anahp Compliance Excellence Seal for the second time, confirming a trajectory centered on ethics, integrity, and regulatory compliance.

Innovation with Artificial Intelligence

Rede Mater Dei de Saúde has deployed an artificial intelligence assistant integrated into electronic health records across Belo Horizonte and metropolitan region facilities. The tool assists physicians in documenting consultation data, reducing administrative burden, streamlining clinical workflows, and ensuring greater focus on patient safety.





Advances in Healthcare Quality


- ❑ Oncology care extended to all RMBH facilities following the opening of the dedicated oncology center at Santo Agostinho, designed to offer integrated care, cutting-edge technology, and personalized treatment.
- ❑ Expansion of robotic surgery across all states of operation through the acquisition of the Da Vinci robotic system at Mater Dei Goiânia.
- ❑ First CAR-T Cell therapy infusions performed in Belo Horizonte, establishing the hospital as the sole private center in Minas Gerais to offer the therapy.

Revenue


Volume

Gross revenue is primarily composed of healthcare services rendered—including inpatient admissions, surgeries, oncology, medical consultations, and exams—whether through health insurance operators, self-managed entities, government bodies, or out-of-pocket patients.

The third quarter of 2026 presented an average of 1,239 operational beds, a slight increase of 14 beds compared to 2Q26, evidencing dynamic and efficient bed management to support revenue expansion and a better specialty mix. The quarterly occupancy rate reached 83.8%, in line with the established strategy, being 2.1 p.p. higher compared to the same quarter of the previous year and stable compared to 2Q26.




Compared to 2Q26, patient-day volume and the average number of operational beds grew in the same proportion (1%), while compared to 3Q25, there was a 1.2% increase in patient-day volume and a slight 0.6% reduction in the number of beds, in line with the Company's strategy of operating with higher occupancy rates aimed at operational efficiency.



Revenue

Ticket and Consolidated Values

The consolidated average ticket in the third quarter of 2026 advanced 14.6% and 6.5% compared to 3Q25 and 2Q26, respectively, reaching R$ 3.06 million per occupied bed. The strong growth in the annual comparison reflects the improvement in the mix of specialties, procedures, and health plans, driven by the increased representativeness of oncology, surgical bookings, and outpatient revenues; the change in the weight of our hospitals' composition, with the ramp-up of Nova Lima and Salvador; and annual readjustment negotiations with paying sources.



In the third quarter of 2026, gross revenue reached R$ 739.5 million, an increase of 16.0% compared to the third quarter of the previous year and 7.4% above the gross revenue presented in the last quarter, evidencing the Company's sustainable growth.

Gross revenue deductions primarily comprise: (i) provision for disallowances; (ii) federal and municipal taxes levied on revenue; and (iii) canceled billings.

R$ millions	Consolidated							
	3Q26	3Q25	Δ 3Q25	2Q26	Δ 2Q26	9M26	9M25	Δ 9M25
Health Insurances	684.5	591.5	15.7%	641.3	6.7%	1.923,0	1,674.0	14.9%
Private Patient	42.5	36.9	15.1%	36.5	16.4%	115.9	106.3	9.0%
Other revenues	12.6	9.2	37.0%	10.7	17.5%	33.4	27.5	21.6%
Gross Revenue	**739.5**	**637.6**	**16.0%**	**688.5**	**7.4%**	**2,072.3**	**1,807.8**	**14.6%**
Disallowances	(32.1)	(27.8)	15.5%	(30.1)	6.7%	(90.1)	(78.6)	14.7%
Taxes and deductions	(47.3)	(42.0)	12.7%	(44.8)	5.6%	(133.5)	(116.2)	14.8%
Net Revenue	**660.2**	**567.9**	**16.3%**	**613.6**	**7.6%**	**1,849.0**	**1,613.0**	**14.6%**

Costs

Costs of Services Provided

The cost of services rendered is formed mainly by materials and medicines, personnel, medical services rendered, depreciation and amortization, and maintenance and conservation.

In 3Q26, the costs of services rendered totaled R$ 451.0 million, representing 68.3% of net revenue, a drop of 1.6 p.p. compared to 3Q25 and 1.3 p.p. compared to 2Q26. These reductions are explained by the dilution of costs across all lines through revenue growth, with the exception of the Mat/Med line, which presented a natural increase given the greater relevance and representativeness of the oncology line in the results.

Consequently, the reported Gross Profit was R$ 209.1 million, while the gross margin reached 31.7%, since the effects on the cost of services rendered impact the margin in the same proportion.

R$ millions	Consolidated							
	3Q26	3Q25	Δ 3Q25	2Q26	Δ 2Q26	9M26	9M25	Δ 9M25
Materials and medicines	(190.2)	(154.8)	22.9%	(170.2)	11.8%	(516.1)	(431.7)	19.5%
% of net revenue	*28.8%*	*27.3%*	*1.5pp*	*27.7%*	*1.1pp*	*27.9%*	*26.8%*	*1,1pp*
Personnel	(121.6)	(110.9)	9.7%	(116.5)	4.4%	(351.9)	(321.3)	9.5%
% of net revenue	*18.4%*	*19.5%*	*(1.1pp)*	*19.0%*	*(0.6pp)*	*19.0%*	*19.9%*	*(0.9pp)*
Medical services rendered	(65.0)	(59.7)	8.8%	(66.7)	(2.6%)	(192.3)	(172.2)	11.7%
% of net revenue	*9.8%*	*10.5%*	*(0.7pp)*	*10.9%*	*(1.1pp)*	*10.4%*	*10.7%*	*(0.3pp)*
Maintenance and conservation	(24.4)	(23.1)	5.6%	(24.8)	(1.4%)	(73.3)	(67.6)	8.5%
% of net revenue	*3.7%*	*4.1%*	*(0.4pp)*	*4.0%*	*(0.3pp)*	*4.0%*	*4.2%*	*(0.2pp)*
Depreciation and amortization	(21.5)	(22.4)	-4.3%	(21.4)	0.4%	(63.9)	(66.4)	-3.8%
% of net revenue	*3.3%*	*3.9%*	*(0.6pp)*	*3.5%*	*(0.2pp)*	*3.5%*	*4.1%*	*(0.6pp)*
Other costs	(28.4)	(25.8)	9.8%	(27.4)	3.5%	(81.4)	(74.0)	9.9%
% of net revenue	*4.3%*	*4.5%*	*(0.2pp)*	*4.5%*	*(0.2pp)*	*4.4%*	*4.6%*	*(0.2pp)*
Cost of services rendered	**(451.0)**	**(396.7)**	**13.7%**	**(426.9)**	**5.7%**	**(1,279.0)**	**(1,133.2)**	**12.9%**
% of net revenue	*68.3%*	*69.9%*	*(1.6pp)*	*69.6%*	*(1.3pp)*	*69.2%*	*70.3%*	*(1.1pp)*
Gross Profit	**209.1**	**171.1**	**22.2%**	**186.7**	**12.0%**	**569.8**	**479.7**	**18.8%**
Gross Margin %	*31.7%*	*30.1%*	*1.6pp*	*30.4%*	*1.3pp*	*30.8%*	*29.7%*	*1.1pp*

Expenses

General, Administrative and Other

General and administrative (SG&A) expenses consist primarily of corporate personnel, administrative depreciation, and shared-service back-office activities.

In 3Q26, SG&A expenses accounted for 12.3% of net revenue (-0.2 p.p. vs. 3Q25). This reduction is due to lower personnel expenses driven by revenue dilution. Regarding net operating expenses—which mainly include provisions/reversals for lawsuits, allowance for doubtful accounts, and equity income—the growth in the quarter was impacted by higher allowances for doubtful accounts; losses on property and equipment write-offs; and the reimbursement of contingencies from former partners in 2Q26, without the same effect in 3Q26. Compared to the same quarter of the previous year, the variation is mainly explained by higher provisions for doubtful accounts.


R$ millions	Consolidated							
	3Q26	**3Q25**	**Δ 3Q25**	**2Q26**	**Δ 2Q26**	**9M26**	**9M25**	**Δ 9M25**
Personnel	(45.4)	(41.7)	9.0%	(43.8)	3.8%	(132.3)	(127.5)	3.7%
% of net revenue	*6.9%*	*7.3%*	*(0.4pp)*	*7.1%*	*(0.2pp)*	*7.2%*	*7.9%*	*(0.7pp)*
Depreciation and amortization	(8.1)	(5.3)	51.4%	(8.0)	1.3%	(23.8)	(15.8)	50.9%
% of net revenue	*1.2%*	*0.9%*	*0.3pp*	*1.3%*	*(0.1pp)*	*1.3%*	*1.0%*	*0.3pp*
Third-party services	(19.8)	(17.5)	13.0%	(16.4)	20.9%	(51.3)	(46.4)	10.5%
% of net revenue	*3.0%*	*3.1%*	*(0.1pp)*	*2.7%*	*0.3pp*	*2.8%*	*2.9%*	*(0.1pp)*
Other expenses	(7.6)	(6.4)	20.1%	(7.3)	4.2%	(20.7)	(16.6)	24.3%
% of net revenue	*1.2%*	*1.1%*	*0.1pp*	*1.2%*	*-*	*1.1%*	*1.0%*	*0.1pp*
General and admin. expenses	**(80.9)**	**(70.9)**	**14.2%**	**(75.4)**	**7.3%**	**(228.0)**	**(206.4)**	**10.5%**
% of net revenue	*12.3%*	*12.5%*	*(0.2pp)*	*12.3%*	*-*	*12.3%*	*12.8%*	*(0.5pp)*
Other operational rev./exp.	(9.5)	(2.2)	342.0%	(2.1)	358.1%	(18.3)	(18.0)	1.9%
% of net revenue	*1.4%*	*0.4%*	*1.0pp*	*0.3%*	*1.1pp*	*1.0%*	*1.1%*	*(0.1pp)*
Net operational expenses	**(90.4)**	**(73.0)**	**23.8%**	**(77.5)**	**16.7%**	**(246.3)**	**(224.3)**	**9.8%**
% of net revenue	*13.7%*	*12.9%*	*0.8pp*	*12.6%*	*1.1pp*	*13.3%*	*13.9%*	*(0.6pp)*

EBIT and EBITDA

Operating Result

Adjusted EBITDA in the quarter reached R$ 148.2 million, an increase of 7.0% compared to 2Q26 and significant growth of 17.8% compared to 3Q25. This expansion was essentially supported by revenue increment through the evolution of the average ticket, volume growth, and the maturation of new units. The Adjusted EBITDA margin reached 22.5%, stable compared to 2Q26 and 0.3 pp higher compared to 3Q25, driven by (i) greater cost/expense dilution and (ii) rigorous control of personnel lines to maximize profitability resulting from the company's growth.

R$ millions	Consolidated							
	3Q26	3Q25	Δ 3Q25	2Q26	Δ 2Q26	9M26	9M25	Δ 9M25
Gross revenue	**739.5**	**637.6**	**16.0%**	**688.5**	**7.4%**	**2,072.3**	**1,807.8**	**14.6%**
Taxes, deductions & disallowances	(79.4)	(69.7)	13.9%	(74.8)	6.1%	(223.6)	(194.8)	14.8%
Net Revenue	**660.2**	**567.9**	**16.3%**	**613.6**	**7.6%**	**1,848.8**	**1,613.0**	**14.6%**
Cost of services rendered	(451.0)	(396.7)	13.7%	(426.9)	5.7%	(1,279.0)	(1,133.2)	12.9%
Net Operational Expenses	(90.4)	(73.0)	23.8%	(77.5)	16.7%	(246.3)	(224.3)	9.8%
EBIT	**118.7**	**98.1**	**21.0%**	**109.3**	**8.7%**	**323.5**	**255.4**	**26.6%**
% of net revenue	*18.0%*	*17.3%*	*0.7pp*	*17.8%*	*0.2pp*	*17.5%*	*15.8%*	*1.7pp*
Depreciation and Amortization	29.5	27.8	6.4%	29.3	0.6%	87.7	82.2	6.7%
EBITDA	**148.2**	**125.9**	**17.8%**	**138.6**	**7.0%**	**411.2**	**337.6**	**21.8%**
% of net revenue	*22.5%*	*22.2%*	*0.3pp*	*22.6%*	*(0.1pp)*	*22.2%*	*20.9%*	*1.3pp*
Complementary Profit Sharing Provision	-	-	-	-	-	5.6	-	-
Adjusted EBITDA	**148.2**	**125.9**	**17.8%**	**138.6**	**7.0%**	**416.8**	**337.6**	**23.4%**
% of net revenue	*22.5%*	*22.2%*	*0.3pp*	*22.6%*	*(0.1pp)*	*22.5%*	*20.9%*	*1.6pp*



Net Financial Result

Financial Income and Expenses

In the quarter, the net financial result recorded a 2.2% improvement vs 2Q26, driven primarily by the reduction in interest expenses on loans and financing, reflecting (i) the early redemption of R$ 200 million from the 3rd debenture issuance, (ii) the lower average Selic rate, and (iii) the reduction in the average cost of debt. These factors were partially offset by the contraction in financial revenue and the net effect of the swap.


Compared to 3Q25, net financial expenses reduced by 24.9%, benefiting from the lower average gross indebtedness in the period, as well as the drop in the Selic rate and the cost of debt.

R$ millions	Consolidated							
	3Q26	3Q25	Δ 3Q25	2Q26	Δ 2Q26	9M26	9M25	Δ 9M25
Financial Revenue	**24.0**	**30.2**	**(20.4%)**	**28.4**	**(15.3%)**	**78.2**	**86.7**	**(9.7%)**
Financial Expense	**(65.7)**	**(85.7)**	**(23.3%)**	**(71.0)**	**(7.4%)**	**(206.9)**	**(227.7)**	**(9.1%)**
Interest on loans, financing, installments and acquisitions	(34.9)	(55.0)	(36.5%)	(47.5)	(26.5%)	(126.2)	(148.9)	(15.2%)
Lease interest	(20.2)	(19.1)	5.7%	(20.1)	0.4%	(60.2)	(56.6)	6.3%
Others	(10.6)	(11.6)	(8.3%)	(3.4)	209.6%	(20.5)	(22.2)	(7.7%)
Net Financial Result	**(41.7)**	**(55.5)**	**(24.9%)**	**(42.6)**	**(2.2%)**	**(128.7)**	**(141.1)**	**(8.8%)**



Net Income

In the current quarter, net income reached R$ 52.5 million, a 90.9% increase compared to 3Q25 and 16.6% vs 2Q26, while the net margin reached 7.9%, registering a growth of 3.1 pp in the annual comparison and 0.6 pp vs 2Q26. These better net income results are explained by the effects that resulted in the EBITDA growth and the reduction of financial expenses, as described above.



R$ millions	Consolidated							
	3Q26	**3Q25**	**Δ 3Q25**	**2Q26**	**Δ 2Q26**	**9M26**	**9M25**	**Δ 9M25**
EBIT	118.7	98.1	21.0%	109.3	8.7%	323.5	255.4	26.6%
Net financial result	(41.7)	(55.5)	(24.9%)	(42.6)	(2.2%)	(128.7)	(141.1)	(8.8%)
EBT (Earnings Before Taxes)	**77.0**	**42.6**	**80.8%**	**66.6**	**15.6%**	**194.8**	**114.4**	**70.3%**
Income Tax and Social Contribution	(24.6)	(15.1)	62.5%	(21.7)	13.5%	(64.7)	(39.6)	63.5%
Net Income	**52.5**	**27.5**	**90.9%**	**45.0**	**16.6%**	**130.0**	**74.7**	**74.0%**
% of net revenue	*7.9%*	*4.8%*	*3.1pp*	*7.3%*	*0.6pp*	*7.0%*	*4.6%*	*2.4pp*
Complementary Profit Sharing Provision	-	-	-	-	-	3.7	-	-
Adjusted Net Income	**52.5**	**27.5**	**90.9%**	**45.0**	**16.6%**	**133.7**	**74.7**	**78.9%**
% of net revenue	*7.9%*	*4.8%*	*3.1pp*	*7.3%*	*0.6pp*	*7.2%*	*4.6%*	*2.6pp*


Debt

In 3Q26, the net debt balance totaled R$ 731 million, a reduction of R$ 32.5 million (-4.3%) compared to 2Q26, driven by robust operational cash flow. Compared to 3Q25, net debt decreased by R$ 7.1 million (-1.0%), even after funding the R$ 56 million buyout of remaining Hospital Santa Clara shares and paying dividends above the statutory minimum in late 2025. Financial leverage (Net Debt / LTM EBITDA) reached 1.4x (down 0.1x QoQ and 0.4x YoY), reflecting LTM EBITDA expansion.


Consolidated (R$ millions)	3Q26	3Q25	Δ 3Q25	2Q26	Δ 2Q26
Short-term debt	88	93	-5.1%	114	-22.8%
Long-term debt	1.059	1.325	-20.1%	1.277	-17.1%
Gross Debt[1]	**1.147**	**1.417**	**-19.1%**	**1.391**	**-17.6%**
Cash, equivalents and financial investments	416	680	-38.8%	628	-33.7%
Net Debt	**731**	**738**	**-1.0%**	**763**	**-4.3%**
EBITDA LTM[1]	537	418	28.7%	516	4.2%
Net Debt / EBITDA LTM	*1.4*	*1.8*	*-0.4*	*1.5*	*-0.1*


1. As per the Company's debenture issuance covenants

To demonstrate underlying cash flow generation across recent quarters, the chart below illustrates a pro-forma debt exercise excluding shareholder remuneration (share buybacks and net dividends paid/received). Over the past 12 months, pro-forma net debt would have fallen by R$ 71 million, implying an adjusted leverage ratio of 1.2x at the end of 3Q26. Below, chart with net debt (R$ mn) and accumulated buybacks/dividends (R$ mn):



Mater Dei's weighted average debt maturity stands at 4.67 years (vs. 4.98 years in 2Q26). Total borrowing cost in 3Q26 stood at CDI - 0.98% p.a.






Excludes transaction costs.

Cash Flow

In 3Q26, operating cash flow before working capital was R$ 148 million, with working capital consuming R$ 22 million. Net operating cash flow was completed after R$ 62 million in interest payments (principally semiannual debenture coupons) and R$ 23 million in income taxes.

Investing activities totaled R$ 39 million. In addition, there was a negative variation of R$ 7 million in other lines that make up the cash flow. Cash reached R$ 624 million excluding share buybacks, M&A settlements, and the early debenture redemption—declining by just R$ 4 million despite the semiannual obligations of the Debentures, evidencing our efforts to transform the Network's operational performance into Cash.



*contains the effect of the cash amortization of the commercial lease

Appendix

P&L

(In thousands of Reais)	3Q26	3Q25	2Q26	9M26	9M25
Gross revenue	**739,528**	**637,565**	**688,461**	**2,072,311**	**1,807,782**
Health Insurances	684,474	591,490	641,255	1,922,998	1,673,972
Private Patient	42,453	36,877	36,480	115,908	106,344
Other revenues	12,601	9,198	10,726	33,405	27,466
Taxes and deductions	**(79,363)**	**(69,708)**	**(74,828)**	**(223,555)**	**(194,800)**
Net revenue	**660,165**	**567,857**	**613,633**	**1,848,756**	**1,612,982**
Cost of services rendered	**(451,032)**	**(396,737)**	**(426,901)**	**(1,278,970)**	**(1,133,249)**
Materials and medicines	(190,212)	(154,787)	(170,198)	(516,093)	(431,699)
Personnel	(121,607)	(110,867)	(116,454)	(351,942)	(321,301)
Medical services rendered	(64,978)	(59,719)	(66,696)	(192,293)	(172,194)
Maintenance and conservation	(24,407)	(23,103)	(24,766)	(73,326)	(67,584)
Depreciation and amortization	(21,457)	(22,429)	(21,378)	(63,936)	(66,447)
Other costs	(28,371)	(25,832)	(27,409)	(81,380)	(74,024)
Gross profit	**209,133**	**171,120**	**186,732**	**569,786**	**479,733**
General and administrative expenses	**(80,899)**	**(70,863)**	**(75,398)**	**(228,030)**	**(206,353)**
Personnel	(45,434)	(41,678)	(43,762)	(132,295)	(127,534)
Depreciation and amortization	(8,062)	(5,327)	(7,958)	(23,795)	(15,773)
Third-party services	(19,777)	(17,506)	(16,356)	(51,278)	(46,422)
Other expenses	(7,626)	(6,352)	(7,322)	(20,662)	(16,624)
Equity equivalence result	**640**	**(165)**	**256**	**990**	**(1,424)**
Other operational rev./exp.	**(10,151)**	**(1,987)**	**(2,332)**	**(19,290)**	**(16,541)**
Income before financial result	**118,723**	**98,105**	**109,258**	**323,456**	**255.415**
Financial revenues	24,049	30,202	28,393	78,230	86,654
Financial expenses	(65,731)	(85,706)	(71,014)	(206,914)	(227,717)
Net financial result	**(41,682)**	**(55,504)**	**(42,621)**	**(128,684)**	**(141,063)**
EBT (Earnings Before Taxes)	**77,041**	**42,601**	**66,637**	**194,772**	**114,352**
Total Income Tax and Social Contribution	**(24,565)**	**(15,119)**	**(21,650)**	**(64,743)**	**(39,606)**
Net income for the period	**52,476**	**27,482**	**44,987**	**130,029**	**74,746**
Complementary Profit Sharing Provision	-	-	-	3,703	-
Adjusted net income for the period	**52,476**	**27,482**	**44,987**	**133,732**	**74,746**
Net income attributable to controlling shareholders	**52,425**	**26,865**	**44,245**	**129,875**	**73,031**
Net income attributable to non-controlling shareholders	**51**	**617**	**742**	**154**	**1,715**
				-	

(In thousands of Reais)	3Q26	3Q25	2Q26	9M26	9M25
EBIT	**118,723**	**98,105**	**109,258**	**323,456**	**255,415**
Depreciation and amortization	29,519	27,756	29,336	87,731	82,220
EBITDA	**148,242**	**125,861**	**138,594**	**411,187**	**337,635**
Complementary Profit Sharing Provision	-	-	-	5,610	-
Adjusted EBITDA	**148,242**	**125,861**	**138,594**	**416,797**	**337,635**

Appendix

Balance Sheet

(In thousands of Reais)	30/09/2026	30/09/2025	31/12/2025
Assets			
Current			
Cash and Cash Equivalents	392,699	654,027	599,130
Financial investment	23,444	25,516	26,328
Accounts receivable from customers	801,512	742,217	717,064
Inventories	88,276	64,261	71,785
Accounts receivable from works	44,620	42,710	43,195
Other current assets	34,066	34,198	36,591
Total current assets	**1,384,617**	**1,562,929**	**1,494,093**
Non-Current			
Accounts receivable from works	234,254	266,937	259,168
Judicial deposits	66,148	57,390	60,666
Deferred IR and CSLL (Income Tax and Social Contribution)	177,987	231,401	234,266
Investments	12,277	11,837	11,506
Right of use	675,648	675,117	665,852
Property, plant and equipment	813,349	814,564	811,604
Intangible assets	729,990	730,981	730,498
Other non-current assets	61,314	49,781	45,236
Total non-current assets	**2,770,967**	**2,838,008**	**2,818,796**
Total assets	**4,155,584**	**4,400,937**	**4,312,889**
Liabilities			
Current			
Suppliers	163,891	143,809	148,566
Loans and financing ST	85,823	89,945	112,332
Derivative financial instruments	2,292	2,951	2,599
Commercial leasing ST	80,165	71,533	78,371
Salaries and social charges	87,808	90,076	66,891
Taxes and contributions payable	39,591	39,939	38,519
Tax installments ST	70	463	338
Accounts payable for acquisition of companies	69,623	26,888	30,761
Share redemption liability	2,383	58,369	2,383
Other current liabilities	7,442	11,019	10,346
Total current liabilities	**539,088**	**534,992**	**491,106**
Non-Current			
Loans and financing LT	1,042,616	1,300,903	1,290,122
Derivative financial instruments	16,239	23,611	20,361
Commercial leasing LT	724,652	708,009	698,427
Tax installments LT	508	541	508
Deferred IR and CSLL (Income Tax and Social Contribution)	52,547	77,019	74,362
Accounts payable for acquisition of companies	88,098	141,460	141,639
Provision for contingencies	121,501	113,919	110,241
Other non-current liabilities	7,407	7,801	8,549
Total non-current liabilities	**2,053,568**	**2,373,263**	**2,344,209**
Shareholders' Equity			
Share Capital	1,301,019	1,301,019	1,301,019
Capital reserve and Profit for the Period	272,025	202,951	140,898
Profit reserves	90,368	41,537	90,659
(-) Treasury shares	(16,280)	(2,423)	(6,303)
Patrimonial valuation adjustment	(98,743)	(80,269)	(61,785)
Total shareholders' equity	**1,548,389**	**1,462,815**	**1,464,488**
Non-controlling shareholders' interest	14,539	29,867	13,086
Total shareholders' equity	**1,562,928**	**1,492,682**	**1,477,574**
Total liabilities	**4,155,584**	**4,400,937**	**4,312,889**

Appendix
Cash Flow

(In thousands of Reais)	30/09/2026	30/09/2025
Cash flow from operating activities		
Net income for the period	130,029	74,746
Adjustments to reconcile surplus to net cash		
Depreciation and amortization	87,731	82,220
Loss on write-off of property, plant, and equipment and intangible assets	3,959	3,180
Constitution (reversal) of allowance for doubtful accounts	21,230	12,045
Constitution (reversal) of provision for disallowances	70,056	13,317
Constitution (reversal) of provision for contingencies	(3,361)	7,543
Provision for share-based payment	1,252	3,439
Equity equivalence result	(990)	1,424
Result with derivatives	7,319	6,153
Income from financial investments	(50,227)	(62,659)
Net financial expenses	166,113	191,846
Provision for current and deferred IR and CSLL	(6,437)	(2,781)
	426,674	**330,473**
Variation in operational assets and liabilities		
Accounts receivable	(177,788)	(106,995)
Inventories	(10,754)	(14,504)
Other assets	11,050	13,900
Judicial deposits	(1,701)	(6,213)
Suppliers	19,022	14,005
Salaries and social charges	20,917	32,781
Taxes and contributions payable	57,287	39,181
Installment taxes	(268)	(5,614)
Other liabilities	2,484	1,190
	(79,751)	**(32,269)**
Income tax and social contribution paid	(56,215)	(23,060)
Interest paid	(162,090)	(137,468)
Net cash generated by operating activities	**128,618**	**137,676**
Cash flow from investing activities		
Acquisition of property, plant and equipment	(67,020)	(30,638)
Acquisition of intangibles	(10,211)	(9,986)
Capital Contribution/AFAC	(478)	-
Acquisition of investments	(28,417)	(35,179)
Financial investments made, net of redemptions	53,111	89,878
Net cash used in investing activities	**(53,015)**	**14,075**
Cash flow from financing activities		
Borrowings and financing raised	-	700,000
Payments of loans and financing	(244,765)	(747,420)
Lease payments	(21,142)	(17,892)
Settlement of derivatives	(6,592)	(4,711)
Treasury shares	(9,977)	(35,509)
Dividends paid	442	(14,773)
Net cash generated (used) in financing activities	**(282,034)**	**(120,305)**
INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	**(206,431)**	**31,446**
Cash and cash equivalents at the beginning of the period	599,130	622,581
Cash and cash equivalents at the end of the period	392,699	654,027
INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	**(206,431)**	**31,446**

Glossary and Other Information

AoP: Average of period

LTM: Last Twelve Months

IFRS 16: As of January 1st, 2019, all companies had to adapt to the new rules of IFRS 16, With this new standard, lessees now have to recognize the asset of rights over leased assets and the liability of future payments for medium or long-term leases, including operating leases, The biggest impact we had was on the real estate lease contracts of our operational and administrative units,

EBITDA: Earnings before Interest, Taxes, Depreciation and Amortization

EBITDA Margin: EBITDA divided by net revenue

EBIT: Earnings before Interest and Taxes

CDI: Interbank Deposit Certificate

Occupancy rate: Number of beds occupied by patients per day added up over a given period, divided by the number of beds that were operational each day added up during the same period.

About Rede Mater Dei de Saúde

Rede Mater Dei de Saúde is an integrated platform that provides hospital and cancer services, being a national reference in health and the largest private hospital network in Minas Gerais, The Company has more than 2,200 beds of capacity in its 9 units located in the metropolitan region of Belo Horizonte ("RMBH"), Salvador, Uberlândia, Goiânia and Feira de Santana,

Rede Mater Dei has a clinical expertise that is recognized by patients, medical community, healthcare operators, suppliers, and relevant sectors of the Brazilian Society, and focuses on innovation and medical pioneering,

Relationship with independent auditors

In accordance with CVM Resolution CVM 162/22, we inform that our policy for hiring independent auditors considers the best governance principles, which reserve the auditor's independence, in accordance with internationally accepted criteria,

For additional Investor Relations information, please access the website: https://ri,materdei,com,br/en/ or e-mail ri@materdei,com,br

This material contains summary information, which is not intended to be complete and should not be considered by shareholders or potential investors as an investment recommendation, Information about Mater Dei, its activities, economic and financial situation, and the risks inherent to its activities, as well as its financial statements, can be obtained on the world wide web, on the Mater Dei website (https://ri,materdei,com,br/en/)





HUB BRASIL CENTRAL
Mater Dei Goiânia
Goiânia/GO

Mater Dei Santa Clara
Uberlândia/MG

Mater Dei Santa Genoveva
Uberlândia/MG

Mater Dei CDI
Uberlândia/MG

SÃO PAULO
Mater Dei São Paulo
[em construção]

HUB BAHIA
Mater Dei Salvador
Salvador/BA

Mater Dei Emec
Feira de Santana/BA

HUB RMBH
Mater Dei Santo Agostinho
Belo Horizonte/MG

Mater Dei Contorno
Belo Horizonte/MG

Mater Dei Betim-Contagem
Betim/MG

Mater Dei Nova Lima
Nova Lima/MG